Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NO-13065 Phase 1 Study in Healthy and Obese Adults
NCT04838639Phase 1Completed
- Sponsor
- Otsuka Pharmaceutical Factory, Inc.
- Start
- Jun 2021
- Primary completion
- Mar 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in obesity comparing NO-13065 with Placebo (2 arms). Primary endpoint: Treatment Emergent Adverse Events up to 35 days. Started Jun 2021; status: completed.
02
Drugs
NO-13065
03
Conditions
obesity
Beyond the preview
Go deeper on NCT04838639.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04838639.